🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Today, we announced our financial results for the first quarter of 2025. We continue to see strong momentum in our launch. Join our investment community webcast at 9 a.m. ET / 2 p.m. BST: bit.ly/432cFct #VRNA

Congratulations to our CDO Tara Rheault on her inclusion in the The Medicine Maker Power List 2025! We’re pleased to see Tara recognized among other small molecule #drugdevelopment leaders for her dedication to advancing therapeutic solutions for #respiratorydiseases. Review the

Verona Pharma has been named a winner in the Triangle Business Journal 2025 Life Sciences Awards. We are proud to be part of a life sciences community working to make a difference in peoples’ lives – and to be recognized for our efforts to advance the field of respiratory care. See the

We’re heading to #ATS2025! We are pleased to announce we are presenting 10 posters including seven on additional analyses of our #Phase3 ENHANCE trials, two from nonclinical studies and one from a real-world data analysis. If you are attending ATS, stop by our booth, 2237, and

On #InternationalNursesDay, we celebrate the nurses who make a difference in the lives of people with #COPD and #respiratorydiseases. Thank you for your commitment to patients.

We are honored to be shortlisted for the Breakthrough of the Year, Company of the Year and the Best Communication Awards at the European Mediscience Awards 2025 (#EMA25)! This recognition underscores the dedicated efforts of our team and partners in delivering breakthrough

On Sunday, in partnership with the Bronchiectasis and NTM Association, we participated in San Francisco’s iconic #BaytoBreakers (B2B) 12k race! We are proud to raise awareness on behalf of those affected by #bronchiectasis and #NTMlungdisease, and work towards improving the lives

Verona Pharma is on the ground at #ATS2025, engaging with the leading minds in respiratory medicine. If you’re attending, let’s connect – we look forward to meaningful discussions. #COPD #RespiratoryDisease

Don’t miss Verona Pharma at the Jefferies Global Healthcare Conference and the Goldman Sachs 46th Annual Global Healthcare Conference next month. Tune into our fireside chats here bit.ly/435bSYm. #JefferiesHealthcare #LifeSciences #BioPharma #InvestorRelations $VRNA

Chris Martin, Verona Pharma’s Chief Commercial Officer, speaks to Philip Hemme @Flotbio about how to launch a biotech product.

For those with #COPD, allergens like dust, pet dander and pollen can make symptoms worse. #RespiratoryHealth

Non-Cystic Fibrosis Bronchiectasis (#bronchectasis) affects ~370K adults in the US & has no targeted FDA-approved therapies. At Verona Pharma, we are committed to developing innovative prescription medicines for #respiratoryconditions like bronchiectasis. Learn more:

We are honored to be named one of the Best Places to Work in the Triangle for the second year in a row! Thank you to our skilled team that is committed to quality, excellence, and impact.

We are proud to have won two awards at the @European Mediscience Awards 2025: Breakthrough of the Year and Company of the Year! Thank you to MediscienceAwards for this honor, and to the Verona team and our partners for your commitment to delivering innovative treatments for patients.

Meet Rachel Hunter, CPA, Verona’s Vice President of Finance! Rachel leads our finance team and supports our growth as we deliver on our mission of improving the health and quality of life for patients affected by chronic #respiratorydiseases. #BreathofInnovation

One year ago, on June 26, 2024, the US FDA approved our novel therapy. 365 days later, we are more encouraged than ever by the potential of our therapy to help patients. #BreathofInnovation

Today is #WorldBronchiectasisDay. At Verona Pharma, we are committed to enhancing the lives of patients affected with #respiratoryconditions. We are developing a potential therapy for non-cystic fibrosis bronchiectasis (#bronchiectasis), a disease with currently no FDA-approved